Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has received an average rating of “Moderate Buy” from the four ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and three have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $19.00.

A number of equities research analysts have recently issued reports on the company. Wall Street Zen cut Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Enanta Pharmaceuticals in a report on Wednesday, September 23rd.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Hillsdale Investment Management Inc. bought a new position in Enanta Pharmaceuticals during the fourth quarter worth about $6,660,000. Spruce Street Capital LP bought a new stake in Enanta Pharmaceuticals in the 2nd quarter valued at about $15,873,698. Janus Henderson Group PLC boosted its holdings in Enanta Pharmaceuticals by 1.5% in the 1st quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock valued at $47,717,000 after purchasing an additional 54,396 shares during the period. Jupiter Topco LLC bought a new stake in Enanta Pharmaceuticals in the 2nd quarter valued at about $53,252,000. Finally, BlackRock Inc. acquired a new position in shares of Enanta Pharmaceuticals during the 2nd quarter worth approximately $47,304,000. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Price Performance

Shares of ENTA opened at $12.84 on Friday. The company’s 50-day moving average is $13.12 and its 200-day moving average is $13.29. The firm has a market capitalization of $373.90 million, a PE ratio of -5.33 and a beta of 0.96. Enanta Pharmaceuticals has a fifty-two week low of $10.09 and a fifty-two week high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.16). The company had revenue of $14.36 million for the quarter, compared to the consensus estimate of $16.76 million. Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%. Analysts predict that Enanta Pharmaceuticals will post -2.36 earnings per share for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and other diseases. The company’s research has primarily centered on antiviral medicines, including treatments for respiratory syncytial virus (RSV), hepatitis B, and other infectious diseases.

Enanta is best known for its role in the development of glecaprevir, a protease inhibitor used with pibrentasvir in AbbVie’s Mavyret (also marketed as Maviret) treatment for chronic hepatitis C virus infection.